자가 줄기세포 및 비줄기세포 치료 시장 : 치료법 유형별, 적응증별, 세포원별, 투여 경로별, 가공 레벨별, 최종 사용자별 시장 예측(2026-2032년)

The Autologous Stem Cell & Non-Stem Cell Therapies Market is projected to grow by USD 18.01 billion at a CAGR of 16.23% by 2032.

Autologous stem cell and non-stem cell therapies use a patient's own cells to repair tissue, restore immune function, or target disease, reducing risks linked to donor matching and graft-versus-host disease. The category includes established procedures such as autologous hematopoietic stem cell transplantation, rapidly advancing CAR-T cell therapy, tumor-infiltrating lymphocyte therapy, autologous cell-based regenerative medicine, platelet-rich plasma, chondrocyte implantation, and other personalized cellular interventions.

Market momentum is being shaped by validated clinical adoption in oncology and hematology, expanding evidence in musculoskeletal and autoimmune indications, and regulatory pathways for advanced therapy medicinal products and human cells, tissues, and cellular and tissue-based products. For relevance, the strongest demand signals are concentrated around autologous cell therapy, personalized regenerative medicine, CAR-T manufacturing, stem cell transplantation, cell processing, cell therapy supply chain, and point-of-care cell therapy platforms.

Transformative Shifts in the Therapy Landscape

The landscape is shifting from procedure-led cell harvesting toward standardized, digitally controlled, and closed-system manufacturing. Hospitals, contract development and manufacturing organizations, and biopharma sponsors are investing in automated leukapheresis integration, cryopreservation, chain-of-identity systems, chain-of-custody controls, and release testing designed to shorten vein-to-vein time for patient-specific therapies.

Clinical strategy is also changing. Autologous therapies are moving beyond late-line oncology into earlier treatment settings where durable response, lower relapse risk, and real-world evidence can support stronger clinical value. At the same time, cost, scalability, reimbursement, sterility assurance, manufacturing consistency, and patient eligibility remain key barriers that shape commercial success.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across autologous stem cell and non-stem cell therapy development. AI-driven image analysis, multi-omics interpretation, and predictive analytics support patient selection, potency assessment, release decision support, and adverse event monitoring, especially in complex immunotherapies where cell phenotype and functional activity influence outcomes.

In manufacturing, AI can support batch-failure prediction, process parameter optimization, automated quality review, deviation detection, and logistics forecasting. These applications are most valuable when paired with validated data governance, Good Manufacturing Practice controls, secure patient data handling, bias monitoring, and explainable models that regulators and clinicians can audit.

Key Regional Insights

Asia-Pacific is a high-growth region for autologous cell therapies, supported by Japan's regenerative medicine framework, China's expanding clinical trial base, South Korea's biotechnology capabilities, India's cost-sensitive hospital networks, and Australia's strong translational research infrastructure. Demand is strongest where oncology centers, transplant programs, regenerative medicine institutes, and cell processing facilities are integrated with manufacturing capacity and clinical governance.

North America remains the most commercially mature region, led by the United States through FDA-regulated cell and gene therapy approvals, advanced academic medical centers, accredited transplant programs, and specialized reimbursement models. Canada contributes through regulated stem cell transplantation networks and clinical research capacity. Latin America shows selective growth through Brazil and Mexico, where oncology access, private hospital systems, and regulatory oversight influence adoption. Europe benefits from the European Medicines Agency's advanced therapy framework and strong clinical centers in Germany, France, Italy, Spain, and the United Kingdom. The Middle East is gaining traction through GCC investments in specialty hospitals, transplantation, and precision medicine, while Africa remains an emerging opportunity where infrastructure, affordability, workforce training, and regulatory harmonization are decisive factors.

Key Group Insights

ASEAN markets are developing through medical tourism, oncology center expansion, and growing interest in regenerative medicine, although regulatory maturity and quality enforcement vary across member states. The GCC is investing in tertiary care, transplant services, national genomics, and precision medicine programs that can support controlled adoption of autologous therapies, particularly where specialized hospitals and international clinical partnerships are expanding.

The European Union provides one of the clearest regulatory structures for advanced therapy medicinal products, supporting cross-border clinical development while maintaining strict manufacturing, pharmacovigilance, traceability, and quality requirements. BRICS countries create scale advantages through large patient populations, expanding clinical trial activity, and growing biomanufacturing capability, while G7 markets remain central for clinical validation, reimbursement evidence, regulatory precedent, and premium launches. NATO countries, while not a healthcare market bloc, overlap with many advanced economies that prioritize supply-chain security, hospital readiness, cold-chain resilience, and biomedical preparedness.

Key Country Insights

The United States leads in commercial autologous immunotherapy adoption, supported by FDA approvals, major cancer centers, accredited cell therapy programs, and a dense manufacturing ecosystem. Canada shows steady uptake through transplant and oncology networks, while Mexico is gaining attention as a regional access hub, provided therapies meet rigorous safety, ethics, and quality standards. Brazil is Latin America's strongest platform for clinical research scale, hematology expertise, and public-private healthcare demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical trial capacity with established transplant programs, academic hospitals, and reimbursement scrutiny. Russia has scientific capability and transplant expertise but faces access, funding, and collaboration constraints. China is expanding rapidly in CAR-T research and hospital-based trials, India is building affordability-focused capacity and regulated cell therapy infrastructure, Japan benefits from regenerative medicine policy support and conditional approval mechanisms, Australia offers strong clinical governance and trial networks, and South Korea combines bioprocessing expertise with advanced hospital infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that links clinical outcomes with manufacturability, cost per successful treatment, time to treatment, and long-term safety. Robust registries, real-world evidence programs, standardized adverse event tracking, and harmonized potency assays can strengthen payer confidence and accelerate broader adoption of autologous cell therapies.

Organizations should invest in closed and automated manufacturing, decentralized collection networks, validated cryogenic logistics, digital chain-of-identity and chain-of-custody platforms, and workforce training for cell therapy operations. Strategic partnerships with academic medical centers, certified transplant units, regional manufacturing partners, and qualified logistics providers can reduce implementation risk while improving patient access.

Research Methodology

This executive summary is developed using secondary research from regulatory agencies, peer-reviewed literature, clinical trial registries, clinical practice guidance, hospital adoption patterns, and publicly available information from organizations involved in cell therapy, transplantation, and regenerative medicine. Emphasis is placed on verified market signals, approved therapy pathways, and documented infrastructure trends rather than unsubstantiated claims.

The analytical framework evaluates therapy type, clinical indication, manufacturing model, regulatory pathway, reimbursement environment, regional access, clinical evidence maturity, and technology adoption. Insights are triangulated across clinical evidence, policy developments, commercial approvals, safety requirements, and infrastructure readiness to support decision-making for executives, investors, and healthcare stakeholders.

Conclusion

Autologous stem cell and non-stem cell therapies are advancing from specialized clinical procedures into a more structured personalized medicine market. Their value proposition is strongest where patient-specific biology, durable response, controlled manufacturing, and robust clinical monitoring converge.

Future adoption will depend on scalable production, credible clinical evidence, payer-aligned outcomes, validated quality systems, equitable access models, and responsible integration of artificial intelligence. Organizations that combine scientific rigor with operational excellence will be best positioned to lead the next phase of autologous cell therapy commercialization.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Therapy Type

• 7.1. Non Stem Cell Therapy
  • 7.1.1. Exosomes
  • 7.1.2. Platelet Rich Plasma
    • 7.1.2.1. Leukocyte Poor Prp
    • 7.1.2.2. Leukocyte Rich Prp
  • 7.1.3. Stromal Vascular Fraction
• 7.2. Stem Cell Therapy
  • 7.2.1. Hematopoietic Stem Cells
    • 7.2.1.1. Bone Marrow Derived
    • 7.2.1.2. Cord Blood Derived
    • 7.2.1.3. Peripheral Blood Derived
  • 7.2.2. Induced Pluripotent Stem Cells
  • 7.2.3. Mesenchymal Stem Cells
    • 7.2.3.1. Adipose Tissue Derived
    • 7.2.3.2. Bone Marrow Derived
    • 7.2.3.3. Umbilical Cord Derived

8. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication

• 8.1. Cardiovascular
  • 8.1.1. Ischemic Heart Disease
  • 8.1.2. Myocardial Infarction
  • 8.1.3. Peripheral Artery Disease
• 8.2. Dermatology
  • 8.2.1. Hair Restoration
  • 8.2.2. Skin Rejuvenation
  • 8.2.3. Wound Healing
• 8.3. Neurology
  • 8.3.1. Neurodegenerative Disorders
  • 8.3.2. Spinal Cord Injury
  • 8.3.3. Stroke
• 8.4. Orthopedics
  • 8.4.1. Bone Defects
  • 8.4.2. Cartilage Repair
  • 8.4.3. Osteoarthritis
  • 8.4.4. Tendon Injuries
• 8.5. Rheumatology
  • 8.5.1. Osteoarthritis
  • 8.5.2. Psoriasis
  • 8.5.3. Rheumatoid Arthritis

9. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Cell Source

• 9.1. Adipose Tissue
• 9.2. Bone Marrow
• 9.3. Peripheral Blood
• 9.4. Umbilical Cord
  • 9.4.1. Cord Blood
  • 9.4.2. Whartons Jelly

10. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Administration Route

• 10.1. Intra Articular
  • 10.1.1. Hip Joint
  • 10.1.2. Knee Joint
  • 10.1.3. Shoulder Joint
• 10.2. Intradermal
• 10.3. Intramuscular
• 10.4. Intravenous
  • 10.4.1. Peripheral Infusion
  • 10.4.2. Portal Vein Infusion
• 10.5. Subcutaneous

11. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Manipulation Level

• 11.1. Extensive Manipulation
  • 11.1.1. Culture Expanded
  • 11.1.2. Genetic Modification
• 11.2. Minimal Manipulation

12. Autologous Stem Cell & Non-Stem Cell Therapies Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Clinics
  • 12.2.1. Cardiology Clinics
  • 12.2.2. Cosmetic Clinics
  • 12.2.3. Orthopedic Clinics
• 12.3. Hospitals
• 12.4. Research Institutes
  • 12.4.1. Academic Institutes
  • 12.4.2. Government Labs
  • 12.4.3. Private Research Labs

13. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Anterogen Co., Ltd.
• 17.2. Bluebird Bio, Inc.
• 17.3. Brainstorm Cell Therapeutics, Inc.
• 17.4. Bristol-Myers Squibb Company
• 17.5. Cambium Bio Limited
• 17.6. Castle Creek Biosciences Inc.
• 17.7. Cytori Therapeutics Inc.
• 17.8. Dendreon Pharmaceuticals LLC
• 17.9. Gilead Sciences, Inc.
• 17.10. Globus Medical Inc
• 17.11. HCA International Limited
• 17.12. Hemogenyx Pharmaceuticals PLC
• 17.13. Hemostemix Inc.
• 17.14. Jasper Therapeutics, Inc.
• 17.15. Juventas Therapeutics, Inc.
• 17.16. Kolon TissueGene, Inc.
• 17.17. Lisata Therapeutics, Inc.
• 17.18. Medipost Co., Ltd.
• 17.19. NOVADIP Biosciences S.A.
• 17.20. Novartis AG
• 17.21. Stempeutics Research Pvt. Ltd.
• 17.22. Vericel Corporation